Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Aging Male. 2020 Dec;23(5):1059-1065. doi: 10.1080/13685538.2019.1666814. Epub 2019 Sep 18.
The best method for administering testosterone replacement therapy (TRT) for late-onset hypogonadism (LOH) remains controversial. This study aimed to compare the efficacy and safety of a combined treatment (CT) involving intramuscular testosterone injection and testosterone ointment application [Glowmin (GL)] with intramuscular injection monotherapy (IMIM).
Patients were randomly assigned as follows: Group 1 received IMIM for 12 weeks and CT for 12 weeks and Group 2 received CT for 12 weeks and IMIM for 12 weeks. Patients were then asked about their treatment preferences: (A) IMIM, (B) a combination of IMIM and ointment, or (C) either A or B.
Patients ( = 43) completed the study without any adverse effects. No significant differences between each treatment period were found. In Group 1, most patients chose B ( = 13) while in Group 2, most chose A ( = 10). In each group, patients preferred the second treatment phase; however, statistical significance was not reached between A and B (Group 1, = 0.11 and Group 2, = 0.47, respectively).
TRT by CT is compatible with TRT by IMIM. Patients who cannot continue TRT because of polycythemia from IMIM may be suited to CT.
对于迟发性性腺功能减退症（LOH）的睾丸激素替代疗法（TRT）的最佳方法仍存在争议。本研究旨在比较肌内注射睾丸激素和睾丸激素软膏应用（Glowmin[GL]）联合治疗（CT）与肌内注射单药治疗（IMIM）的疗效和安全性。
患者被随机分为以下两组：第 1 组接受 12 周肌内注射和 12 周 CT 治疗，第 2 组接受 12 周 CT 和 12 周肌内注射治疗。然后，患者被问及他们的治疗偏好：（A）IMIM，（B）IMIM 和软膏的组合，或（C）A 或 B。
无任何不良反应的情况下，所有患者（ = 43）均完成了研究。每个治疗期之间均未发现显著差异。在第 1 组中，大多数患者选择 B（ = 13），而在第 2 组中，大多数患者选择 A（ = 10）。在每组中，患者都更喜欢第二个治疗阶段；然而，A 和 B 之间没有达到统计学意义（组 1， = 0.11，组 2， = 0.47）。
CT 的 TRT 与 IMIM 的 TRT 兼容。由于 IMIM 引起的红细胞增多症而无法继续 TRT 的患者可能适合 CT。
